Geron Corporation reports results for the quarter ended September 30 - Earnings Summary

• Geron Corporation reported quarterly breakeven results​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -3 cents. The mean expectation of five analysts for the quarter was for a loss of one cent per share. Wall Street expected results to range from -2 cents tozero cents per share.

• Revenue rose 27.4% to $60.19 million from a year ago; analysts expected $60.35 million.

• Geron Corporation's reported EPS for the quarter was breakeven results​.

• The company reported quarterly net income of $1.35 million.

• Geron Corporation shares had fallen by 24.4% this quarter and lost 29.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 8.3% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Geron Corporation is $3.50, about 73.4% above its last closing price of $0.93

This summary was machine generated from LSEG data November 4 at 03:12 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)